Bisphosphonates: mechanism of action and role in clinical practice

wbldb

Drake, Matthew T.¹; Clarke, Bart L.¹; Khosla, Sundeep¹

Bisphosphonates: mechanism of action and role in clinical practice

Mayo Clin Proc. September 2008;83(9):1032-1045

©2008 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Affiliations

¹Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN
Abstract

Bisphosphonates are primary agents in the current pharmacological arsenal against osteoclast-mediated bone loss due to osteoporosis, Paget disease of bone, malignancies metastatic to bone, multiple myeloma, and hypercalcemia of malignancy. In addition to currently approved uses, bisphosphonates are commonly prescribed for prevention and treatment of a variety of other skeletal conditions, such as low bone density and osteogenesis imperfecta. However, the recent recognition that bisphosphonate use is associated with pathologic conditions including osteonecrosis of the jaw has sharpened the level of scrutiny of the current widespread use of bisphosphonate therapy. Using the key words bisphosphonate and clinical practice in a PubMed literature search from January 1, 1998, to May 1, 2008, we review current understanding of the mechanisms by which bisphosphonates exert their effects on osteoclasts, discuss the role of bisphosphonates in clinical practice, and highlight some areas of concern associated with bisphosphonate use.
Links

DOI: 10.4065/83.9.1032

PubMed: 18775204

WoS: 000259052800011
History

Revised: 2008-09-1

Online: 2011-10-20

Cited Works (25)

Year	Entry
2007	Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo S-B, Shane E. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. October 2007;22(10):1479-1491.
2004	Chesnut CH III, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. August 2004;19(8):1241-1249.
2000	Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone. November 2000;27(5):687-694.
2003	Burr DB, Miller L, Grynpas M, Li J, Boyde A, Mashiba T, Hirano T, Johnston CC. Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs. Bone. December 2003;33(6):960-969.
2005	Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CYC. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. March 2005;90(3):1294-1301.
1996	Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone. February 1996;18(2):75-85.
1966	Fleisch H, Russell RGG, Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature. November 26, 1966;212:901-903.
1998	Luckman SP, Hughes DE, Coxon FP, Russell RGG, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. April 1998;13(4):581-589.
2007	Chapurlat RD, Arlot M, Burt‐Pichat B, Chavassieux P, Roux JP, Portero‐Muzy N, Delmas PD. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long‐term bisphosphonates: a bone biopsy study. J Bone Miner Res. October 2007;22(10):1502-1509.
2004	Bone HG, Hosking D, Devogelaer J-P, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA; Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. NEJM. March 18, 2004;350(12):1189-1199.
1998	Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ; Fracture Intervention Trial Research Group. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. December 23, 1998;280(24):2077-2082.
2001	Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mellström D, Oefjord ES, Marcinowska-Suchowierska E, Salmi J, Mulder H, Halse J, Sawicki AZ, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. NEJM. May 10, 2001;344(19):1434-1441.
1999	Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD; Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. October 13, 1999;282(14):1344-1352.
1995	Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch LJ, Karpf DB; Group, Alendronate Phase III Osteoporosis Treatment Study. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. NEJM. November 30, 1995;333(22):1437-1443.
1996	Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. December 7, 1996;348(9041):1535-1541.
2003	Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. September 2003;61(9):1115-1117.
2003	Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ; PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. NEJM. September 25, 2003;349(13):1207-1215.
2001	McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Wasnich RD, Greenwald M, Kaufman J-M, Chesnut CH, Reginster J-Y; Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women: Hip Intervention Program Study Group. NEJM. February 1, 2001;344(5):333-340.
2006	Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR; FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA. December 27, 2006;296(24):2927-2938.
2007	Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. NEJM. May 3, 2007;356(18):1809-1822.
2005	Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ; PaTH Study Investigators. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. NEJM. August 11, 2005;353(6):555-565.
2002	Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SAA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA. July 17, 2002;288(3):321-333.
1999	Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. November 1999;104(10):1363-1374.
2002	Riggs BL, Melton LJ III. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res. January 2002;17(1):11-14.
2007	Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S; HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. NEJM. November 1, 2007;357(18):1799-1809.

Cited By (40)

Year	Entry
2010	Gourion-Arsiquaud S, Allen MR, Burr DB, Vashishth D, Tang SY, Boskey AL. Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity. Bone. March 2010;46(3):666-672.
2013	Burket JC, Brooks DJ, MacLeay JM, Baker SP, Boskey AL, van der Meulen MCH. Variations in nanomechanical properties and tissue composition within trabeculae from an ovine model of osteoporosis and treatment. Bone. January 2013;52(1):326-336.
2020	Rossi M, Buonuomo PS, Battafarano G, Conforti A, Mariani E, Algeri M, Pelle S, D’Agostini M, Macchiaiolo M, De Vito R, Gonfiantini MV, Jenkner A, Rana I, Bartuli A, Del Fattore A. Dissecting the mechanisms of bone loss in Gorham-Stout disease. Bone. January 2020;130:115068.
2020	Fontalis A, Eastell R. The challenge of long-term adherence: the role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis. Bone. July 2020;136:115336.
2021	Hildebrand S, Cunningham J. Is there a role for bisphosphonates in vascular calcification in chronic kidney disease? Bone. January 2021;142:115751.
2022	Trivedi T, Guise TA. Systemic effects of abnormal bone resorption on muscle, metabolism, and cognition. Bone. January 2022;154:116245.
2022	Jara MA, Varghese J, Hu MI. Adverse events associated with bone-directed therapies in patients with cancer. Bone. May 2022;158:115901.
2022	Lee LR, Holman AE, Li X, Vasiljevski ER, O'Donohue AK, Cheng TL, Little DG, Schindeler A, Biggin A, Munns CF. Combination treatment with growth hormone and zoledronic acid in a mouse model of osteogenesis imperfecta. Bone. June 2022;159:116378.
2022	Borggaard XG, Roux J-P, Delaisse J-M, Chavassieux P, Andreasen CM, Andersen TL. Alendronate prolongs the reversal-resorption phase in human cortical bone remodeling. Bone. July 2022;160:116419.
2022	Zhou P, Zheng T, Zhao B. Cytokine-mediated immunomodulation of osteoclastogenesis. Bone. November 2022;164:116540.
2020	Raina DB, Liu Y, Jacobson OLP, Tanner KE, Tägil M, Lidgren L. Bone mineral as a drug-seeking moiety and a waste dump: a review. Bone Joint Res. October 2020;9(10):709-718.
2019	Hadaya D, Gkouveris I, Soundia A, Bezouglaia O, Boyce RW, Stolina M, Dwyer D, Dry SM, Pirih FQ, Aghaloo TL, Tetradis S. Clinically relevant doses of sclerostin antibody do not induce osteonecrosis of the jaw (ONJ) in rats with experimental periodontitis. J Bone Miner Res. January 2019;34(1):171-181.
2020	Hain BA, Jude B, Xu H, Smuin DM, Fox EJ, Elfar JC, Waning DL. Zoledronic acid improves muscle function in healthy mice treated with chemotherapy. J Bone Miner Res. February 2020;35(2):368-381.
2020	Cline‐Smith A, Axelbaum A, Shashkova E, Chakraborty M, Sanford J, Panesar P, Peterson M, Cox L, Baldan A, Veis D, Aurora R. Ovariectomy activates chronic low‐grade inflammation mediated by memory t cells, which promotes osteoporosis in mice. J Bone Miner Res. June 2020;35(6):1174-1187.
2020	Sing C, Kiel DP, Hubbard RB, Lau WCY, Li GHY, Kung AWC, Wong ICK, Cheung C. Nitrogen‐containing bisphosphonates are associated with reduced risk of pneumonia in patients with hip fracture. J Bone Miner Res. September 2020;35(9):1676-1684.
2021	Yang G, Collins JM, Rafiee R, Singh S, Langaee T, McDonough CW, Holliday LS, Wang D, Lamba JK, Kim YS, Pelliccioni GA, Vaszilko M, Kosa JP, Balla B, Lakatos PA, Katz J, Moreb J, Gong Y. SIRT1 gene SNP rs932658 is associated with medication‐related osteonecrosis of the jaw. J Bone Miner Res. February 2021;36(2):347-356.
2021	Omosule CL, Gremminger VL, Aguillard AM, Jeong Y, Harrelson EN, Miloscio L, Mastaitis J, Rafique A, Kleiner S, Pfeiffer FM, Zhang A, Schulz LC, Phillips CL. Impact of genetic and pharmacologic inhibition of myostatin in a murine model of osteogenesis imperfecta. J Bone Miner Res. April 2021;36(4):739-756.
2022	Duran I, Zieba J, Csukasi F, Martin JH, Wachtell D, Barad M, Dawson B, Fafilek B, Jacobsen CM, Ambrose CG, Cohn DH, Krejci P, Lee BH, Krakow D. 4-PBA treatment improves bone phenotypes in the Aga2 mouse model of osteogenesis imperfecta. J Bone Miner Res. April 2022;37(4):675-686.
2022	Perrier N, Lang BH, Farias LCB, Poch LL, Sywak M, Almquist M, Vriens MR, Yeh MW, Shariq O, Duh Q-Y, Yeh R, Vu T, LiVolsi V, Sitges-Serra A. Surgical aspects of primary hyperparathyroidism. J Bone Miner Res. November 2022;37(11):2373-2390.
2023	Diaz-delCastillo M, Gundesen MT, Andersen CW, Nielsen AL, Møller HEH, Vinholt PJ, Asmussen JT, Kristensen IB, Nyvold CG, Abildgaard N, Andersen TL, Lund T. Increased bone volume by ixazomib in multiple myeloma: 3-month results from an open label phase 2 study. J Bone Miner Res. May 2023;38(5):639-649.
2023	Shoung A, Shoung N, Hii R, Nerlekar N, Ebeling PR, Rodríguez AJ. Electrocardiogram changes following intravenous bisphosphonate infusion: a systematic review and meta-analysis. J Bone Miner Res. November 2023;38(11):1679-1688.
2011	Center JR, Bliuc D, Nguyen ND, Nguyen TV, Eisman JA. Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab. April 2011;96(4):1006-1014.
2021	Genest F, Claußen L, Rak D, Seefried L. Bone mineral density and fracture risk in adult patients with hypophosphatasia. Osteoporos Int. February 2021;32(2):377-385.
2013	Burket JC. Alterations in Tissue Composition and Nanomechanical Properties With Ageing, Osteoporosis, and Treatment [PhD thesis]. Ithaca, NY: Cornell University; January 2013.
2019	Bakr M. Parathyroid Hormone Effect on Facilitating Stress Fracture Repair [PhD thesis]. Brisbane, Australia: Griffith University; July 2019.
2022	Swallow EA. Approaches to Improve the Structure and Function of the Skeleton in Chronic Kidney Disease [PhD thesis]. Indianapolis, IN: Indiana University; March 2022.
2018	Raina DB. Biomaterials as Carriers for Bone Active Molecules: An Approach to Create Off-the-Shelf Bone Substitutes [PhD thesis]. Lund, Sweden: Lund University; 2018.
2019	Strakhov I. The Nanoscale Structure of Human Female Osteoporotic Bone Investigated by Transmission Electron Microscopy [Master's thesis]. Hamilton, ON: McMaster University; September 2019.
2018	Groenen KHJ. Spinal (in)stability in Metastatic Bone Disease: Experimental, Computational, and Clinical Perspectives [PhD thesis]. Radboud University; 2018.
2022	van Dijk Christiansen P. The Relevance of Reversal Cells and Intermittent Parathyroid Hormone on the Duration of the Reversal-Resorption Phase in Intracortical Bone Remodeling Events [PhD thesis]. University of Southern Denmark (SDU); November 2022.
2013	Wu Y. Compositional and Material Properties of Rat Bone After Drug Treatment [PhD thesis]. Edmonton, AB: University of Alberta; 2013.
2020	Hadaya D. Osteonecrosis of the Jaws: Investigations Into Pathophysiology and Prevention [PhD thesis]. Los Angeles (UCLA), University of California; 2020.
2018	Dillstrom D. Systematic Optimization of Bone Pharmaceuticals to Maximize Therapeutic Response in Conditions of Low Bone Mass [PhD thesis]. University of Michigan; 2018.
2019	Colón-Bernal ID. Unraveling Chemical Composition Heterogeneity of Type I Collagen in Trabecular Bone as a Function of Disease and Treatment [PhD thesis]. University of Michigan; 2019.
2019	Surowiec R. Novel Models to Image and Quantify Bone Drug Efficacy and Disease Progression in Vivo: Addressing the Fragility Phenotype [PhD thesis]. University of Michigan; 2019.
2021	Lo CH. Bone Microenvironmental Control of Skeletal Malignancy [PhD thesis]. University of South Florida; 2021.
2018	Burke MV. Quantification of Changes in Vertebral Bone Quality in the Presence of Metastases [PhD thesis]. University of Toronto; 2018.
2019	Mei X. Microfluidic Platform for Investigating Osteocyte Mechanoregulation of Breast Cancer Bone Metastasis [Master's thesis]. University of Toronto; 2019.
2019	Poon A. Pamidronate Does Not Affect Cortical Porosity in Transgenic Mice Overexpressing Osteoblastic Gαs [Master's thesis]. University of Toronto; 2019.
2020	Coates BA. The Role of Gene Transcription and Inflammatory Cytokines in Bone Fracture Repair [PhD thesis]. St. Louis, MO: Washington University in St. Louis; May 2020.